III: Driving collaborative evidence generation – Improving the scientific quality of evaluations

- Science-based, modernised regulatory approaches and improved collaboration ☺
  - Importance to keep the right balance between availability of new (and needed) products and ever more detailed data requirements out of scientific interest, but not fully relevant to VMP evaluation
- Full support for improved, regular communication of benefits and safety of authorised new products and future technologies to the public – incl. rationale for decision-making
- Importance of international dimension for development of novel approaches is recognised and much appreciated by industry
- Strong support for global harmonised PhV systems & risk-based, modernised approach
  - Development in dialogue with all stakeholders involved
- Improve regulatory science ("science-informed") and move away from worst case scenarios
  - Benefit-risk assessment must prevail – both for new and existing products
- Tailored and targeted risk assessments as a way to safeguard medicines availability
  - Avoid confusion between substance (hazard assessment) and product (exposure and risk assessment)